Further mechanistic investigations using advanced human cell assays and syngeneic mouse models confirm the strong immunogenic effects and anti-tumor efficacy as a result of Nedd8 deletion in ICB-treated TNBC cells. The gene discussed is NEDD8; the disease is neoplasm.